Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai, Astellas Experience Delays In Seeking U.S. Drug Approvals

This article was originally published in PharmAsia News

Executive Summary

Eisai and Astellas Pharma separately announced delays in seeking U.S. approval for new drugs, Eisai for more than a year. Eisai said the decision to put off applying for its E7389 (eribulin mesylate) cancer drug would affect the company's long-term business goals. But President Haruo Naito added the company expects to garner more sales at the beginning of its eventual marketing effort as a result. Astellas said it would delay filing for a new formulation of its Prograf (tacrolimus) as a liver transplant immunosuppressant by three months because the U.S. FDA said it needed that time to review the application. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts